IHC-P analysis of human breast carcinoma tissue using GTX50463 Chk1 antibody. Left : Primary antibody Right : Primary antibody pre-incubated with the antigen specific peptide
IHC-P analysis of human breast carcinoma tissue using GTX50463 Chk1 antibody. Left : Primary antibody Right : Primary antibody pre-incubated with the antigen specific peptide
Chk1 antibody
GTX50463
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetCHEK1
Overview
- SupplierGeneTex
- Product NameChk1 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:1000. IHC-P: 1:50-1:100. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID1111
- Target nameCHEK1
- Target descriptioncheckpoint kinase 1
- Target synonymscell cycle checkpoint kinase; Checkpoint, S. pombe, homolog of, 1; CHK1; CHK1 checkpoint homolog; Chk1-S; serine/threonine-protein kinase Chk1
- HostRabbit
- IsotypeIgG
- Protein IDO14757
- Protein NameSerine/threonine-protein kinase Chk1
- Scientific DescriptionThe protein encoded by this gene belongs to the Ser/Thr protein kinase family. It is required for checkpoint mediated cell cycle arrest in response to DNA damage or the presence of unreplicated DNA. This protein acts to integrate signals from ATM and ATR, two cell cycle proteins involved in DNA damage responses, that also associate with chromatin in meiotic prophase I. Phosphorylation of CDC25A protein phosphatase by this protein is required for cells to delay cell cycle progression in response to double-strand DNA breaks. Several alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Oct 2011]
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer. Read ML et al., 2017 Sep 14, OncogeneRead more